New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
11:14 EDTATHN, MYL, ISRGOptions with increasing implied volatility: ATHN ISRG MYL
News For ATHN;ISRG;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 21, 2015
19:00 EDTISRGOn The Fly: After Hours Movers
Subscribe for More Information
16:59 EDTISRGIntuitive Surgical advances further to up over 12% in after-hours trading
16:58 EDTISRGIntuitive Surgical sees 2H15 gross profit margin 67%-68%
Subscribe for More Information
16:57 EDTISRGIntuitive Surgical raises 2015 procedural growth view to 11%-13% from 8%-11%
Comments from company's Q2 earnings conference call.
16:43 EDTISRGIntuitive Surgical advances almost 9% after reporting Q2 results
Subscribe for More Information
16:08 EDTISRGIntuitive Surgical Q2 worldwide da Vinci procedures grew 14%
Worldwide da Vinci procedures grew approximately 14% over the second quarter of 2014, up 8% sequentially over the first quarter of 2015, driven primarily by growth in U.S. general surgery procedures and broad-based procedure growth in Asia and other international markets. The Company shipped 118 da Vinci Surgical Systems, compared to 96 in the second quarter of 2014 and 99 in the first quarter of 2015.
16:07 EDTISRGIntuitive Surgical reports Q2 EPS $4.57, consensus $3.98
Subscribe for More Information
15:02 EDTISRGNotable companies reporting after market close
Subscribe for More Information
14:16 EDTISRGIntuitive Surgical July weekly 502.50 straddle priced for 6.4% movement into Q2
Subscribe for More Information
12:33 EDTISRGEarnings Watch: Intuitive Surgical down about 9% since last earnings
Subscribe for More Information
12:16 EDTISRGIntuitive Surgical technical comments before results
The stock has been trading in a sideways range from $480 at the low and $512 at the high since April of this year. Those two bounds may help us understand where price may go following earnings. If the news is bearish, a breakdown below $480 would resolve the range bearishly. Next supports to watch as potential downside objectives would be at $475, $470.79, and $467.45. If the news is a bullish surprise, the upper bound of the range at $512 would likely be tested. A breakout above $512 would resolve the range bullishly. Next resistance levels to watch as potential upside objectives would be at $525.57, $538.83, and $542.41.
08:30 EDTISRGIntuitive Surgical July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
July 20, 2015
08:38 EDTMYLAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:33 EDTMYLInternational AIDS Society to hold a conference
Subscribe for More Information
07:30 EDTMYLZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information
July 17, 2015
08:38 EDTMYLLeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information
06:59 EDTISRGIntuitive Surgical Q2 expectations look reasonable, says Leerink
Subscribe for More Information
July 16, 2015
10:00 EDTATHNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:52 EDTISRGIntuitive Surgical July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
06:15 EDTATHNathenahealth initiated with a Hold at Canaccord
Target $125.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use